jeudi 17 mai 2018

Onco Actu du 17 mai 2018


2.11 Etiologie - Alimentation

In Labeling Coffee a Carcinogen, California Leaps Ahead of the Science [Undark]

3.1.1 Prévention - Tabac - e-cigs

Both Sides of the Vaping Controversy [Conversable Economist]

Vape Pen Explodes, Killing a Man in Florida [NY Times]

4.2 Dép., diag. & prono. - Génome

Implementing and Evaluating Genomic Screening Programs in Health Care Systems [National Academies Press]

5.1 Traitements - Pré-clinique

NIH, Northwestern scientists develop potential new approach to stop cancer metastasis [NIH]

5.12.7 Immunothérapies - vaccins

Is This Stem Cell Clinic Really Making Cancer Vaccines? [Wired]

5.2.3 Pharma - économie

Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million [Forbes]

Novartis announces changes to the Executive Committee [Novartis]

5.3.4 Traitements - AMM (FDA, EMA,...)

Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma [Exelixis]

5.4 Traitements - Economie

Roche gets NICE approval for advanced bladder cancer [Pharmafile]

5.5 ASCO

ASCO 2018: How a major medical meeting uses embargoes to shape the news, and what the consequences may be [HealthNewsReview]

5.5.1 ASCO (général)

ASCO 2018 Preview [OBR blog]

5.5.1.1 ASCO (général) - Industriels

Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections [Janssen]

AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting [AbbVie]

Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions [Celgene]

Loxo Oncology's targeted RET drug shows promise in early trial [Reuters]

Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO [Pfizer]

Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting [Jounce]

New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting [Merck]

Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018 [BMS]

Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [Loxo]

5.5.10 ASCO (hémato)

bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting [bluebird bio]

New Regimens Improve Survival for Children and Young Adults With T-Cell Cancers [ASCO]

5.5.13 ASCO (divers)

More Choices for Treating Insomnia in Cancer Survivors: Acupuncture and Cognitive Behavioral Therapy [ASCO]

Use of Mobile and Sensor Technology Lowers Symptom Severity for People With Head and Neck Cancer [ASCO]

5.5.2 ASCO (sein)

Roche breast cancer drug treatment time can be halved - study [Reuters]

Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects [NPR]

Shorter Trastuzumab Treatment for HER2+ Breast Cancer Can Be as Effective, With Fewer Cardiac Side Effects [ASCO]

Shorter drug treatment OK for many breast cancer patients [AP]

Six months of breast cancer treatment ‘could be as effective as 12’ in some women with early stage disease [Cancer Research UK]

For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter [NY Times]

5.5.8 ASCO (poumon)

Merck's Keytruda boosts response in hard-to-treat lung cancer [Reuters]

Testing for all lung cancer mutations at once found cost effective - study [Reuters]

Merck KGaA's lung cancer drugs show promise in early-stage trials [Reuters]

Roche immunotherapy combination increases lung cancer survival - study [Reuters]

Vast Majority of Heavy Smokers Not Screened for Lung Cancer Despite USPSTF Recommendations [ASCO]

Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death [Roche]

Upfront, Comprehensive Genetic Testing in Advanced Lung Cancer Is Cost-Effective [ASCO]

Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel [Roche]

5.9 AACR

Eleven New Institutions Join AACR Project GENIE Consortium [AACR]

6.1 Observation

Why Is Liver Cancer on the Rise? [Cancer Research Catalyst]

6.10 Politiques

China extends drug patents to 25 years [Asian Review]

6.6 Publications

Sweden Cancels Agreement With Elsevier Over Open Access [The Scientist]

Opinion: Reproducibility failures are essential to scientific inquiry [PNAS]

Nine pitfalls of research misconduct [Nature]

Give every paper a read for reproducibility [Nature]